Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
NCT06085274

Sentinel lympH Node Biopsy With Indocyanine Green in Breast Cancer After NEoadjuvant Chemotherapy (SHINE)

Led by University Health Network, Toronto · Updated on 2025-12-19

100

Participants Needed

1

Research Sites

34 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective, open-label, within-patient clinical trial to determine the accuracy of Indocyanine green (ICG) guided sentinel lymph node biopsy (SLNB) compared to the standard dual-tracer SLNB in breast cancer patients who have had chemotherapy as a first treatment using a non-inferiority design. Patients with operable breast cancer treated with chemotherapy and eligible for SLNB will be included in the study. During surgery, ICG will be injected and used to identify fluorescent sentinel nodes using a hand-held imaging camera; radiotracer and blue dye will also be used as per standard protocols. Intraoperative and clinicopathologic outcomes such as complications, characteristics of nodes, false negative rates and feasibility will be assessed. Patients will be asked to complete standardized patient reported outcome questionnaires (Breast-Q, FACT-B+4, VAS) to define the patient experience with this novel technique.

CONDITIONS

Official Title

Sentinel lympH Node Biopsy With Indocyanine Green in Breast Cancer After NEoadjuvant Chemotherapy (SHINE)

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 80 years
  • Stage I-III invasive breast cancer confirmed by core biopsy
  • Completed neoadjuvant chemotherapy and planned for sentinel lymph node biopsy with dual tracer
  • Eastern Cooperative Oncology Group (ECOG) performance status less than 2
  • No allergy to Indocyanine green or iodine
  • Able to provide informed consent
  • Literate in English
Not Eligible

You will not qualify if you...

  • Significant medical conditions classified as ASA 4
  • Breast cancer stage T4 or inflammatory breast cancer, or N2 disease at presentation
  • Clinically node positive after neoadjuvant therapy
  • Previous axillary surgery or radiotherapy to the same breast or underarm
  • Currently pregnant or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Health Network

Toronto, Ontario, Canada, M5G2M9

Actively Recruiting

Loading map...

Research Team

T

Tulin Cil, MD MSc FRCSC

CONTACT

K

Karineh Kazazian, MD PhD FRCSC

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here